866-997-4948(US-Canada Toll Free)

Neupro - Analysis and Estimates from 2006 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 39 Pages



GlobalDatas pharmaceuticals report, Neupro Analysis and Estimates from 2006 to 2020 provides Neupro sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Neupro including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Neupro including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Neupro in each of the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 5
2.1 Parkinsons Disease 5
2.2 Symptoms of Parkinsons Disease 5
2.3 Diagnosis of Parkinsons disease 6
2.4 Parkinsons Disease Treatment Strategies 6
2.5 Parkinsons Disease Market 7
2.6 Epidemiology 7
2.7 Parkinsons Disease by Age and Gender 7
2.8 Etiology 8
2.9 GlobalData Report Guidance 9

3 Parkinsons Disease: Market Characterization 10
3.1 Parkinsons Disease Market 10
3.2 Parkinsons Disease Market Forecasts and CAGR 10
3.3 Factors Affecting Parkinsons Disease Market 11
3.3.1 High Prevalence: PD is the Second Most Frequent Neurodegenerative Disorder 11
3.3.2 Increase in Old Age Population 11
3.3.3 Patent Expiry of Prominent Drugs 11

4 Stages of Parkinsons Disease and Comparison of Treatments 12
4.1 The Hoehn and Yahr Scale 12
4.2 Modified Hoehn and Yahr Scale 12
4.3 The UPDRS 13

5 Staging of Parkinsons Disease 16
5.1 Distribution of Parkinsons disease Patients by Age Groups 16
5.2 Distribution of Patients by Stages 16

6 Neupro 17
6.1 Introduction 17
6.2 Mechanism of Action 17
6.3 Clinical Studies 17
6.4 Approval History of Neupro 19
6.5 Factors Affecting Sales of Neupro 19
6.5.1 Unique Delivery Mechanism 19
6.5.2 Higher Patient Compliance 19
6.5.3 Wider Target Patient Pool 19
6.5.4 Crystallization Formation 19
6.5.5 Constant Plasma Level Concentration 20
6.6 Drug Evaluation 21
6.6.1 Drug Risk Benefit Score 21
6.6.2 Intensity of Competition 22
6.7 Sales Estimates 23
6.7.1 Target Patient Pool of Neupro 23
6.7.2 Dosing 24
6.7.3 Market Penetration 24
6.7.4 Annual Cost of Therapy 25
6.7.5 Sales Projections of Neupro 25

7 Parkinsons Disease Market: Appendix 35
7.1 Market Definitions 35
7.2 List of Abberiviations 35
7.3 Research Methodology 35
7.3.1 Coverage 35
7.3.2 Secondary Research 35
7.3.3 Forecasting 36
7.3.4 Number of Patients Approved to take the Drug 36
7.3.5 Net Penetration of Drug 36
7.3.6 Net Annual Dosing 37
7.3.7 Annual Cost of Therapy 37
7.3.8 Primary Research 37
7.3.9 Expert Panels 38
7.4 Drug Sales Estimates Model 38
7.5 Contact Us 38
7.6 Disclaimer 39
7.7 Sources 39

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 5
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 12
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 12
Table 4: Four Items, Part 1 of UPDRS 13
Table 5: Thirteen Items, Part 2 of Parkinsons disease 13
Table 6: Fourteen Items, Part 3 of UPDRS 14
Table 7: Fourteen Items, Part 3 of UPDRS 14
Table 8: Distribution of Parkinsons patients according to Hoehn and Yahr Classification 16
Table 9: Approval History of Neupro 19
Table 10: Drug Risk Benefit Score of Neupro 21
Table 11: Safety Comparison 21
Table 12: Efficacy Comparison of Neupro 22
Table 13: Annual Cost of Neupro for Parkinsons Disease, 2010 25
Table 14: Neupro, Parkinsons Disease, Global, Sales Estimates ($m), 20062020 26
Table 15: Neupro, Parkinsons Disease, The US, Sales Estimates ($m), 20072020 27
Table 16: Neupro, Parkinsons Disease, The UK, Sales Estimates ($m), 20062020 28
Table 17: Neupro, Parkinsons Disease, France, Sales Estimates ($m), 20102020 29
Table 18: Neupro, Parkinsons Disease, Germany, Sales Estimates ($m), 20062020 30
Table 19: Neupro, Parkinsons Disease, Italy, Sales Estimates ($m), 20092020 31
Table 20: Neupro, Parkinsons Disease, Spain, Sales Estimates ($m), 20062020 32
Table 21: Neupro, Parkinsons Disease, Japan, Sales Estimates ($m), 20132020 33

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinsons disease and Their Potential Sites of Action in the CNS 6
Figure 2: The Age-Specific Prevalence Rates of Parkinsons Disease in the Elderly Among Five European Countries, 2003 8
Figure 3: Parkinsons Disease, Global, Market Size Estimates ($bn), 20102020 10
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 11
Figure 5: Points Distribution of UPDRS 15
Figure 6: Distribution of Parkinsons patients by Hoehn & Yahr Classification 16
Figure 7: Neupro Plasma Concentration 20
Figure 8: Drug Model Diagram of Neupro 23
Figure 9: Neupro, Parkinsons Disease, Global, Sales Estimates ($m), 20062020 26
Figure 10: Neupro, Parkinsons Disease, The US, Sales Estimates ($m), 20072020 27
Figure 11: Neupro, Parkinsons Disease, The UK, Sales Estimates ($m), 20062020 28
Figure 12: Neupro, Parkinsons Disease, France, Sales Estimates ($m), 20102020 29
Figure 13: Neupro, Parkinsons Disease, Germany, Sales Estimates ($m), 20062020 30
Figure 14: Neupro, Parkinsons Disease, Italy, Sales Estimates ($m), 20092020 31
Figure 15: Neupro, Parkinsons Disease, Spain, Sales Estimates ($m), 20062020 32
Figure 16: Neupro, Parkinsons Disease, Japan, Sales Forecasts ($m), 20132020 33
Figure 17: Neupro, Parkinsons Disease, Sales Distribution by Country (%), 2020 34
Figure 18: Drug Model Diagram 37
Figure 19: Patients Approved for the Drug 37

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *